The current surgical treatment of pancreatic cancer in China: a national wide cross-sectional study
Journal of Pancreatology · 2019
DOI: 10.1097/jp9.0000000000000012 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Journal of Pancreatology, 2019. Verfasst von Wenming Wu und 35 weiteren Autor:innen. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
The aim of this study is to investigate the current status of pancreatic cancer patients undoing surgical treatment in China and to find ways to improve the survival of these patients in the future.
Methods
This study is a national, multicenter, cross-sectional study in China. Information regarding pancreatic cancer patients undergoing surgical treatment from 34 high-volume tertiary IIIA level hospitals was collected and analyzed from the March 1, 2016 to the February 28, 2017.
Results
In total, 2200 pancreatic cancer patients were enrolled from 34 tertiary IIIA level hospitals in 16 provinces across China. The male-to-female ratio was 1.5. More than 80% of the patients were between 50 and 70 years old. The top 4 symptoms were epigastric discomfort, abdominal pain, jaundice, and weight loss. Carbohydrate antigen 19-9 and carcinoembryonic antigen were elevated in 70.9% and 27.1% of patients, respectively. A multidisciplinary team (MDT) discussion was carried out for 35.0% of patients before surgery. The proportion of minimally invasive pancreatic surgeries was approximately 20%. A total of 83.4% of the operations achieved R0 resection, and the incidence of grade 3/4 postoperative complications was 7.7%. Only 13.4% of the patients received postoperative adjuvant chemotherapy. The percentage of pathological stage I tumors was only 24.5%.
Conclusion
The majority of pancreatic cancer patients undergoing surgical resection in China are in an advanced stage. The MDT consultations for pancreatic cancer have not been widely carried out. R0 resection has been achieved in most cases, with relatively low incidence of serious complications, but minimally invasive pancreatic surgery should be further promoted. The application of postoperative chemotherapy remains low. This national, multicentre, cross-sectional study comprehensively presents the current status of pancreatic cancer patients undergoing surgical treatment and shows the road to improve survival of these patients in the future.
Zitieren
APA
Wu, W., Jin, G., Wang, C., Miao, Y., Wang, H., Lou, W., Yu, X., Sun, B., Li, H., Qin, R., Wu, Z., Wang, W., Xu, K., Wang, L., Liang, T., Hao, C., Huang, H., Li, Y., Tan, G., …, & Zhao, Y. (2019). The current surgical treatment of pancreatic cancer in China: a national wide cross-sectional study. Journal of Pancreatology. https://doi.org/10.1097/jp9.0000000000000012
Vancouver
Wu W, Jin G, Wang C, Miao Y, Wang H, Lou W, et al. The current surgical treatment of pancreatic cancer in China: a national wide cross-sectional study. Journal of Pancreatology. 2019. doi:10.1097/jp9.0000000000000012
BibTeX
@article{Wu2019,
author = {Wu, Wenming and Jin, Gang and Wang, Chunyou and Miao, Yi and Wang, Huaizhi and Lou, Wenhui and Yu, Xianjun and Sun, Bei and Li, Haimin and Qin, Renyi and Wu, Zheng and Wang, Weilin and Xu, Kesen and Wang, Lei and Liang, Tingbo and Hao, Chunyi and Huang, Heguang and Li, Yixiong and Tan, Guang and Zhao, Yongfu and Hao, Jihui and Wang, Yifan and Peng, Chenghong and Liu, Xubao and Ou, Jinrui and Yuan, Chunhui and Wang, Xuefeng and Yang, Yinmo and Cai, Shouwang and Guo, Kejian and Jiang, Jianxin and Yu, Xiao and Wei, Junmin and Li, Fei and Wu, Xinmin and Zhao, Yupei},
title = {The current surgical treatment of pancreatic cancer in China: a national wide cross-sectional study},
journal = {Journal of Pancreatology},
year = {2019},
doi = {10.1097/jp9.0000000000000012}
}
EUVIMED